Clinic Value Analysis of Combined Detection of White Blood Cells and T-cell Subgroups in a Patient with SARS-CoV-2 Infection

Jianwei Zhou^1, , Yu Li^{1, 2}, Cui Kong³, Yizhao Li⁴, Qinhua Zhang⁵, Shuheng Hu¹ and Xinke Chen¹

¹Medical Laboratory, Affiliated Hospital of Jining Medical University, Jining, China

²Medical College, Jining Medical University, Jining, China

³Nursing Department, Affiliated Hospital of Jining Medical University, Jining, China

⁴Rehabilitation Department, Fangan Rehabilitation Hospital of Jinan City, Jinan, China

⁵Neurology Department, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Cite this paper:
Jianwei Zhou, Yu Li, Cui Kong, Yizhao Li, Qinhua Zhang, Shuheng Hu and Xinke Chen. Clinic Value Analysis of Combined Detection of White Blood Cells and T-cell Subgroups in a Patient with SARS-CoV-2 Infection. American Journal of Medicine Studies. 2021; 9(1):1-3. doi: 10.12691/ajms-9-1-1

Abstract

To analyze and assess the changes of peripheral blood cells of a patient with SARS-CoV-2 infection, we collected and retrospectively analyzed the white blood cells, T-cell subgroups and interleukin 6 (IL-6) of a patient with COVID-19. Compared to the corresponding normal range, the percent of eosinophiles (ESO%) and count of EOS decreased; the percent of T-cell subgroup with double negative for cluster of differentiation 4 and 8 (CD4^-CD8^- T%) increased. The concentration of IL-6 was 21.5 pg/ml, which far exceeded the normal range (0-3.4 pg/ml). These results indicated that some indices of peripheral blood cells could be taken as reference parameters to assess the infection or severity of SARS-CoV-2.

Keywords:
COVID-19 IL-6 Lymphocyte SARS-CoV-2 T-cell subgroup

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	WHO. WHO Coronavirus Disease (COVID-19) Dashboard - Data last updated: 2021/1/23, 4:57pm CET. 2021, https://covid19.who.int/.
[2]	Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 2020, 75(7): 1730-1741.
[3]	Chen L, Liu .G, Liu W,et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi, 2020, 43(0):E005.
[4]	Li YX, Wu W, Yang T, et al. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19. Zhonghua Nei Ke Za Zhi, 2020. 59(5): 372-374.
[5]	Xu Z, Shi L, Wang Y, Huang L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, 8(4): 420-422.
[6]	Huang Y, Tu M, Wang S, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. Travel Med Infect Dis, 2020, 36: 101606.
[7]	Wang L, Gao YH, Lou LL, et al. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. Eur Respir J, 2020, 55(4): 2000398.
[8]	Zhang G, Zhang J, Wang B, et al. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res, 2020, 21(1): 74.
[9]	Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ, 2020, 27(5): 1451-1454.
[10]	Chu J, Yang N, Wei Y, et al. Clinical Characteristics of 54 Medical Staff With COVID-19: A Retrospective Study in a Single Center in Wuhan, China. J Med Virol, 2020, 92(7): 807-813.
[11]	Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol, 2020, 92(6):577-583.
[12]	Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Sig Transduct Target Ther, 2020, 5(1): 33.
[13]	Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antiviral Res, 2017, 137: 82-92.
[14]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
[15]	Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol, 2020, 17(5): 541-543.
[16]	Wan SX, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol, 2020, 2(7): 797-806.
[17]	Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). 2020, Medrxiv.
[18]	Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect, 2020, 50(4):382-383.
[19]	Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine, 2020, 55:102763.